Eli Lilly increased its revenue from $8,768 million in Q1 2024 to $12,728.5 million in Q1 2025 – resulting in 45.2% year-over-year growth for the top line.

Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a ...

CORBIN, Ky. (LEX 18) — Eight-year-old Eli Hill is a name that resonates deeply within the Corbin community. Though Eli tragically passed away over two years ago, his infectious smile and vibrant ...

Peyton Manning had an embarrassing moment while playing in a pro-am golf event on Wednesday, and you can probably guess whether or not his brother Eli had any sympathy for him.. Peyton was paired ...

Eli Manning has a connection to both as Arch's uncle and Dart as Ole Miss alums drafted by the New York Giants. Manning has plenty of experience to share with both young QBs, ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain and other neuronal hyperexcitability disorders, to advance ...

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Image source: Getty Images. A big catalyst could be coming soon ...

Key Points. Visa, Netflix and Eli Lilly are moving closer to the trillion dollar club. While all three have the potential, one will reach $3 trillion sooner than the others.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

Investing.com -- Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.